Proton Therapy for Recurrent Nasopharyngeal Carcinoma
ConditionRecurrent Nasopharyngeal Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGuangzhou Concord Cancer Center
About this trial
The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and retrospective studies, lacking high-level evidence-based medical evidence. The conduct of this study will explore the safety and efficacy of intensity-modulated proton radiotherapy for recurrent NPC and provide more high-quality evidence-based medical evidence for proton therapy of recurrent cancer.
Eligibility criteria
Qualifiers
Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and/or with positive lymph nodes, (2) Pathological type WHO I-III
PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1.
Expected survival period ≥ 6 months
Before treatment, evaluate the tumor range and size of the patient.
Disqualifiers
Evidence of distant metastasis in stage IVc
Patients with isolated recurrence of cervical lymph nodes;
Patients have participated in other interventional trials for tumors
Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections
Trial design
Treatments tested in this trial
- Proton therapy
- Proton radiation therapy
Treatment groups
52 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov